<p>巴克斯特国际（NYSE:BAX - 获取免费报告）在周五发布给客户和投资者的研究报告中，华尔街证券公司将其目标价格从 21.00 美元下调至 19.00 美元，MarketScreener 报道。该券商目前对这家医疗器械供应商的股票给予 “持平” 评级。华尔街证券公司的价格目标表明，该股票相较于前一交易日收盘价有 0.37% 的潜在下跌空间。</p>
<ul>
<li>医疗科技股票的价值加深：反转即将来临</li>
</ul>
<p>其他几家券商也对 BAX 发布了报告。斯蒂费尔·尼古拉斯在 10 月 31 日的研究报告中将巴克斯特国际的目标价格从 25.00 美元下调至 22.00 美元。杰富瑞金融集团在 10 月 30 日的研究报告中将巴克斯特国际的目标价格从 25.00 美元下调至 21.00 美元，并对该公司给予 “持有” 评级。阿根廷证券在 10 月 31 日的研究报告中将巴克斯特国际的评级从 “买入” 下调至 “持有”。摩根大通在 10 月 31 日的研究报告中将巴克斯特国际的目标价格从 25.00 美元下调至 19.00 美元。最后，考文在 10 月 30 日的报告中重申了对巴克斯特国际的 “持有” 评级。两位证券研究分析师对该股票给予 “买入” 评级，十位分析师给予 “持有” 评级，两位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “持有”，共识目标价格为 22.00 美元。</p>
<p>获取 <strong>巴克斯特国际</strong> 的提醒：</p>
<p><strong>获取我们最新的 BAX 股票报告</strong></p>
<h2>巴克斯特国际股价上涨 0.9%</h2>
<ul>
<li>这 5 家医疗科技公司即将出现重大反转</li>
</ul>
<p>BAX 的股票在周五以 19.07 美元开盘。该公司的债务与股本比率为 1.21，速动比率为 1.18，流动比率为 1.84。该公司的市值为 98 亿美元，市盈率为-28.79，PEG 比率为 1.05，贝塔值为 0.61。该股票的 50 日移动平均价格为 20.07 美元，200 日移动平均价格为 24.45 美元。巴克斯特国际的 52 周低点为 17.40 美元，52 周高点为 37.74 美元。</p>
<p>巴克斯特国际（NYSE:BAX - 获取免费报告）在 10 月 30 日最后发布了季度收益数据。这家医疗器械供应商报告本季度每股收益为 0.69 美元，超出分析师共识预期的 0.60 美元，超出幅度为 0.09 美元。该公司本季度的收入为 28.4 亿美元，而分析师预期为 28.8 亿美元。巴克斯特国际的净利润率为-3.09%，股本回报率为 17.38%。该公司的收入同比增长 5.0%。在去年同期，该公司每股收益为 0.80 美元。巴克斯特国际已将其 2025 年第四季度的指导目标设定为 0.520-0.570 美元每股收益，并将其 2025 财年的指导目标设定为 2.350-2.400 美元每股收益。分析师预测巴克斯特国际在当前财年将发布 2.48 美元每股收益。</p>
<h2>巴克斯特国际的机构交易</h2>
<ul>
<li>购买高收益分红王 3M 的 5 个好理由</li>
</ul>
<p>几家机构投资者和对冲基金最近增加或减少了对 BAX 的持股。Horizon Investments LLC 在第一季度将其在巴克斯特国际的股份增加了 5.0%。Horizon Investments LLC 目前拥有 7438 股该医疗器械供应商的股票，价值 255,000 美元，此前在该期间内增持了 351 股。BI 资产管理公司在第一季度将其在巴克斯特国际的股份增加了 41.7%。BI 资产管理公司目前拥有 20,063 股该医疗器械供应商的股票，价值 687,000 美元，此前在上个季度增持了 5907 股。Ameriprise Financial Inc.在第一季度将其在巴克斯特国际的持股增加了 1.1%。Ameriprise Financial Inc.目前拥有 7540942 股该医疗器械供应商的股票，价值 258,140,000 美元，此前在该期间内增持了 83973 股。Allstate Corp 在第一季度将其在巴克斯特国际的持股增加了 10.5%。Allstate Corp 目前拥有 17,041 股该医疗器械供应商的股票，价值 583,000 美元，此前在上个季度增持了 1621 股。最后，SVB Wealth LLC 在第一季度购买了巴克斯特国际的新股份，价值约 138,000 美元。90.19% 的股票由机构投资者持有。</p>
<h2>巴克斯特国际公司简介</h2>
<p>（获取免费报告）</p>
<p>巴克斯特国际公司通过其子公司在全球开发和提供一系列医疗保健产品。该公司通过四个部门运营：医疗产品与疗法、医疗系统与技术、制药和肾脏护理。该公司提供无菌静脉（IV）溶液；输液系统和设备；肠外营养疗法；通用注射药物；外科止血和密封产品，先进的外科设备；智能床系统；患者监测和诊断技术；以及呼吸健康设备，以及用于外科领域的先进设备，包括外科视频技术、精确定位设备和其他配件。</p>
<h2>另请参阅</h2>
<ul>
<li>五只我们更看好的股票超过巴克斯特国际</li>
<li>今日最大股票亏损者 - 今日最大百分比下跌者</li>
<li>圣诞老人可能会提前到来，给 Palantir 投资者带来惊喜</li>
<li>3 只股票引领了迷因股的复兴</li>
<li>4 只填补重油缺口的加拿大石油股票</li>
<li>道琼斯策略的狗是什么？概述和示例</li>
<li>分红强劲的蓝筹股：为长期投资而生的 3 只股票</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJBWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJBWA"/></p>
<p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在 Baxter International 吗？</h2>
<p>在考虑 Baxter International 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Baxter International 并不在名单上。</p>
<p>虽然 Baxter International 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

<p>富国银行已将百特国际的目标股价从 21.00 美元下调至 19.00 美元，维持 “持平” 评级。其他券商也降低了目标价格，普遍评级为 “持有”，目标价格为 22.00 美元。百特国际的股票开盘价为 19.07 美元，市值为 98 亿美元。该公司报告的季度收益好于预期，收入同比增长 5%</p>

<p>Baxter International (NYSE:BAX - Get Free Report) had its target price reduced by equities researchers at Wells Fargo &amp; Company from $21.00 to $19.00 in a research report issued to clients and investors on Friday,MarketScreener reports. The brokerage presently has an &#34;equal weight&#34; rating on the medical instruments supplier's stock. Wells Fargo &amp; Company's price objective indicates a potential downside of 0.37% from the stock's previous close.</p>
<div class="lb-trans"><p>巴克斯特国际（NYSE:BAX - 获取免费报告）在周五发布给客户和投资者的研究报告中，华尔街证券公司将其目标价格从 21.00 美元下调至 19.00 美元，MarketScreener 报道。该券商目前对这家医疗器械供应商的股票给予 “持平” 评级。华尔街证券公司的价格目标表明，该股票相较于前一交易日收盘价有 0.37% 的潜在下跌空间。</p>
</div><ul>
<li>The Value Deepens for Medtech Stocks: Reversal Imminent</li>
</ul>
<div class="lb-trans"><ul>
<li>医疗科技股票的价值加深：反转即将来临</li>
</ul>
</div><p>Several other brokerages have also issued reports on BAX. Stifel Nicolaus reduced their target price on shares of Baxter International from $25.00 to $22.00 in a research note on Friday, October 31st. Jefferies Financial Group decreased their target price on Baxter International from $25.00 to $21.00 and set a &#34;hold&#34; rating for the company in a research note on Thursday, October 30th. Argus cut Baxter International from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a research note on Friday, October 31st. JPMorgan Chase &amp; Co. cut their price objective on shares of Baxter International from $25.00 to $19.00 in a research report on Friday, October 31st. Finally, Cowen reiterated a &#34;hold&#34; rating on shares of Baxter International in a report on Thursday, October 30th. Two equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat.com, the company currently has a consensus rating of &#34;Hold&#34; and a consensus target price of $22.00.</p>
<div class="lb-trans"><p>其他几家券商也对 BAX 发布了报告。斯蒂费尔·尼古拉斯在 10 月 31 日的研究报告中将巴克斯特国际的目标价格从 25.00 美元下调至 22.00 美元。杰富瑞金融集团在 10 月 30 日的研究报告中将巴克斯特国际的目标价格从 25.00 美元下调至 21.00 美元，并对该公司给予 “持有” 评级。阿根廷证券在 10 月 31 日的研究报告中将巴克斯特国际的评级从 “买入” 下调至 “持有”。摩根大通在 10 月 31 日的研究报告中将巴克斯特国际的目标价格从 25.00 美元下调至 19.00 美元。最后，考文在 10 月 30 日的报告中重申了对巴克斯特国际的 “持有” 评级。两位证券研究分析师对该股票给予 “买入” 评级，十位分析师给予 “持有” 评级，两位分析师给予 “卖出” 评级。根据 MarketBeat.com 的数据，该公司的共识评级为 “持有”，共识目标价格为 22.00 美元。</p>
</div><p>Get <strong>Baxter International</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>巴克斯特国际</strong> 的提醒：</p>
</div><p><strong>Get Our Latest Stock Report on BAX</strong></p>
<div class="lb-trans"><p><strong>获取我们最新的 BAX 股票报告</strong></p>
</div><h2>Baxter International Trading Up 0.9%</h2>
<div class="lb-trans"><h2>巴克斯特国际股价上涨 0.9%</h2>
</div><ul>
<li>A Significant Reversal is in Sight for These 5 Med Tech Companies</li>
</ul>
<div class="lb-trans"><ul>
<li>这 5 家医疗科技公司即将出现重大反转</li>
</ul>
</div><p>Shares of BAX opened at $19.07 on Friday. The company has a debt-to-equity ratio of 1.21, a quick ratio of 1.18 and a current ratio of 1.84. The company has a market cap of $9.80 billion, a price-to-earnings ratio of -28.79, a PEG ratio of 1.05 and a beta of 0.61. The stock has a fifty day moving average price of $20.07 and a two-hundred day moving average price of $24.45. Baxter International has a 52-week low of $17.40 and a 52-week high of $37.74.</p>
<div class="lb-trans"><p>BAX 的股票在周五以 19.07 美元开盘。该公司的债务与股本比率为 1.21，速动比率为 1.18，流动比率为 1.84。该公司的市值为 98 亿美元，市盈率为-28.79，PEG 比率为 1.05，贝塔值为 0.61。该股票的 50 日移动平均价格为 20.07 美元，200 日移动平均价格为 24.45 美元。巴克斯特国际的 52 周低点为 17.40 美元，52 周高点为 37.74 美元。</p>
</div><p>Baxter International (NYSE:BAX - Get Free Report) last issued its quarterly earnings data on Thursday, October 30th. The medical instruments supplier reported $0.69 EPS for the quarter, topping analysts' consensus estimates of $0.60 by $0.09. The firm had revenue of $2.84 billion for the quarter, compared to analyst estimates of $2.88 billion. Baxter International had a negative net margin of 3.09% and a positive return on equity of 17.38%. The company's revenue was up 5.0% on a year-over-year basis. During the same quarter in the prior year, the firm earned $0.80 EPS. Baxter International has set its Q4 2025 guidance at 0.520-0.570 EPS and its FY 2025 guidance at 2.350-2.400 EPS. Analysts predict that Baxter International will post 2.48 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>巴克斯特国际（NYSE:BAX - 获取免费报告）在 10 月 30 日最后发布了季度收益数据。这家医疗器械供应商报告本季度每股收益为 0.69 美元，超出分析师共识预期的 0.60 美元，超出幅度为 0.09 美元。该公司本季度的收入为 28.4 亿美元，而分析师预期为 28.8 亿美元。巴克斯特国际的净利润率为-3.09%，股本回报率为 17.38%。该公司的收入同比增长 5.0%。在去年同期，该公司每股收益为 0.80 美元。巴克斯特国际已将其 2025 年第四季度的指导目标设定为 0.520-0.570 美元每股收益，并将其 2025 财年的指导目标设定为 2.350-2.400 美元每股收益。分析师预测巴克斯特国际在当前财年将发布 2.48 美元每股收益。</p>
</div><h2>Institutional Trading of Baxter International</h2>
<div class="lb-trans"><h2>巴克斯特国际的机构交易</h2>
</div><ul>
<li>5 Good Reasons it's Time to Buy High-Yield Dividend King 3M</li>
</ul>
<div class="lb-trans"><ul>
<li>购买高收益分红王 3M 的 5 个好理由</li>
</ul>
</div><p>Several institutional investors and hedge funds have recently added to or reduced their stakes in BAX. Horizon Investments LLC grew its position in shares of Baxter International by 5.0% in the 1st quarter. Horizon Investments LLC now owns 7,438 shares of the medical instruments supplier's stock valued at $255,000 after acquiring an additional 351 shares during the period. BI Asset Management Fondsmaeglerselskab A S lifted its stake in Baxter International by 41.7% in the 1st quarter. BI Asset Management Fondsmaeglerselskab A S now owns 20,063 shares of the medical instruments supplier's stock valued at $687,000 after purchasing an additional 5,907 shares during the last quarter. Ameriprise Financial Inc. grew its holdings in Baxter International by 1.1% during the first quarter. Ameriprise Financial Inc. now owns 7,540,942 shares of the medical instruments supplier's stock worth $258,140,000 after purchasing an additional 83,973 shares during the period. Allstate Corp increased its position in Baxter International by 10.5% during the first quarter. Allstate Corp now owns 17,041 shares of the medical instruments supplier's stock worth $583,000 after buying an additional 1,621 shares during the last quarter. Finally, SVB Wealth LLC bought a new stake in Baxter International in the first quarter valued at approximately $138,000. 90.19% of the stock is owned by institutional investors.</p>
<div class="lb-trans"><p>几家机构投资者和对冲基金最近增加或减少了对 BAX 的持股。Horizon Investments LLC 在第一季度将其在巴克斯特国际的股份增加了 5.0%。Horizon Investments LLC 目前拥有 7438 股该医疗器械供应商的股票，价值 255,000 美元，此前在该期间内增持了 351 股。BI 资产管理公司在第一季度将其在巴克斯特国际的股份增加了 41.7%。BI 资产管理公司目前拥有 20,063 股该医疗器械供应商的股票，价值 687,000 美元，此前在上个季度增持了 5907 股。Ameriprise Financial Inc.在第一季度将其在巴克斯特国际的持股增加了 1.1%。Ameriprise Financial Inc.目前拥有 7540942 股该医疗器械供应商的股票，价值 258,140,000 美元，此前在该期间内增持了 83973 股。Allstate Corp 在第一季度将其在巴克斯特国际的持股增加了 10.5%。Allstate Corp 目前拥有 17,041 股该医疗器械供应商的股票，价值 583,000 美元，此前在上个季度增持了 1621 股。最后，SVB Wealth LLC 在第一季度购买了巴克斯特国际的新股份，价值约 138,000 美元。90.19% 的股票由机构投资者持有。</p>
</div><h2>Baxter International Company Profile</h2>
<div class="lb-trans"><h2>巴克斯特国际公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.</p>
<div class="lb-trans"><p>巴克斯特国际公司通过其子公司在全球开发和提供一系列医疗保健产品。该公司通过四个部门运营：医疗产品与疗法、医疗系统与技术、制药和肾脏护理。该公司提供无菌静脉（IV）溶液；输液系统和设备；肠外营养疗法；通用注射药物；外科止血和密封产品，先进的外科设备；智能床系统；患者监测和诊断技术；以及呼吸健康设备，以及用于外科领域的先进设备，包括外科视频技术、精确定位设备和其他配件。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另请参阅</h2>
</div><ul>
<li>Five stocks we like better than Baxter International</li>
<li>Biggest Stock Losers - Today’s Biggest Percentage Decliners</li>
<li>Santa Claus May Be Coming Early for Palantir Investors</li>
<li>3 Tickers Leading a Meme Stock Revival</li>
<li>4 Canadian Oil Stocks That Are Filling the Heavy Crude Gap</li>
<li>What is the Dogs of the Dow Strategy? Overview and Examples</li>
<li>Dividend Powerhouses: 3 Blue-Chip Stocks Built for the Long Haul</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票超过巴克斯特国际</li>
<li>今日最大股票亏损者 - 今日最大百分比下跌者</li>
<li>圣诞老人可能会提前到来，给 Palantir 投资者带来惊喜</li>
<li>3 只股票引领了迷因股的复兴</li>
<li>4 只填补重油缺口的加拿大石油股票</li>
<li>道琼斯策略的狗是什么？概述和示例</li>
<li>分红强劲的蓝筹股：为长期投资而生的 3 只股票</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJBWA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx?Prefix=NYSE&amp;Symbol=BAX"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙述科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Baxter International Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Baxter International 吗？</h2>
</div><p>Before you consider Baxter International, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Baxter International 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Baxter International wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Baxter International 并不在名单上。</p>
</div><p>While Baxter International currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Baxter International 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

富国银行公司对百特国际（NYSE:BAX）股票价格发布了悲观的预测